Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 3, 1999, Pages 1620-1625

  McCoy, Kathleen L ^a,b   Matveyeva, Marina ^a   Carlisle, Steven J ^a   Cabral, Guy A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANTIGEN; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; INTERLEUKIN 2; LYSOZYME; MESSENGER RNA; RIMONABANT; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ANIMALS; CANNABINOIDS; CYCLOHEXANOLS; HYBRIDOMAS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MURAMIDASE; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER; TETRAHYDROCANNABINOL; TRANSCRIPTION, GENETIC;

EID: 0033057247     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 330:231-240.
2. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G and Casellas P (1993) Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214:173-180.
3. Cabral GA and Fiacher-Stenger K (1994) Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. Life Sci 54:1831-1844.
4. Chien YH and Davis MM (1993) How alpha beta T-cell receptors 'see' peptide/MHC complexes. Immunol Today 14:597-602.
5. Childers SR and Deadwyler SA (1996) Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 52:819-827.
6. 9-Tetrahydrocannabinol selectively inhibits macrophage coatimulatory activity and down-regulates heat-stable antigen expression. J Pharmacol Exp Ther 277:1315-1321.
7. Coffey RG, Yamamoto Y, Snella E and Pross S (1996) Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem Pharmacol 52:743-751.
8. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR and Martin BR (1993) Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226.
9. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC, Chippari SM, Grego JD, Kullnig RK and Daley GT (1992) Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35:124-135.
10. Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Segui M and Casellas P (1998) The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cells. FEBS Lett 425:419-425.
11. Devane WA, Dysarz FA III, Johnson MR, Melvin LS and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
12. Dove-Pettit DA, Anders DL, Harrison MP and Cabrai GA (1996) Cannabinoid receptor expression in immune cells. Adv Exp Med Biol 402:119-129.
13. Faassen AE and Pierce SK (1995) Cross-linking cell surface class II molecules stimulates Ig-mediated B cell antigen processing. J Immunol 155:1737-1745.
14. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
15. Felder CC, Velutz JS, Williams HL, Briley EM and Matsuda LA (1992) Cannabinoid agonists stimulate both receptor and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42:838-845.
16. 9-Tetrahydrocannabinol inhibition of tumor necrosis factor-α: Suppression of post-translational events. J Pharmacol Exp Ther 267:1558-1565.
17. Galiègue S, Mary S, Marchand J, Dussosoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
18. Germain RN (1994) MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 76:287-299.
19. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
20. Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607-634.
21. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-Κ B/Rel activation. Mol Pharmacol 50: 334-341.
22. Luo YD, Patel MK, Wiederhold MD and Ou DW (1992) Effects of cannabinoids and cocaine on the mitogen-induced transformation of lymphocytes of human and mouse origins. Int J Immunopharmacol 14:49-56.
23. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R and Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478.
24. Matsuda LA (1997) Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 11:143-166.
25. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
26. 9-Tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther 273:1216-1223.
27. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
28. 9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. Proc Soc Exp Biol Med 201:165-168.
29. Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36:189-261.
30. 9-tetrahydrocannabinol (THC) on murine spleen cell populations dependent upon stimulators. Int J Immunopharmacol 14:1019-1027.
31. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Brelière JC and Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
32. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC and Le Fur G (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
33. Schatz AR, Lee M, Condie RB, Pulaski JT and Kaminski NE (1997) Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142:278-287.
34. Singer DF and Linderman JJ (1990) The relationship between antigen concentration, antigen internalization, and antigenic complexes: Modeling insights into antigen processing and presentation. J Cell Biol 111:55-68.
35. 2 receptor mRNA along mouse nephron segments by RT-PCR. Am J Physiol 286:c1453-c1458.
36. 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 256:624-630.
37. 9-THC-DMH. J Pharmacol Exp Ther 263:1383-1390.
38. Watzl B, Scuderi P and Watson RR (1991) Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol 13:1091-1097.
39. Xu X and Pierce SK (1995) The novelty of antigen-processing compartments. J Immunol 155:1652-1654.
40. Zheng Z-M and Specter SC (1996) Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor o maturation and secretion but not its transcription in mouse macrophages. Int J Immunopharmacol 18:53-68.